RxDoctor Payments Data

Jaycee Rolf

Nurse Practitioner · Dothan, ALNPI 1518551571

Payments from drug & device makers

$1,873in general payments, 2019–2025

Across 99 payments — averaging $18.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$560
  • AstraZeneca$413
  • Novo Nordisk$236
  • Bayer$120
  • Exact Sciences$104
  • Lilly USA, LLC$101
  • plus $340 from 9 others

What the payments were for

  • Food & beverage$1,873100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,873 in reported general payments places this provider in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

See all nurse practitioner providers in Alabama

Medicare billing

Part B allowed, 2024
$26,607
Medicare patients
100
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide20$24,298
JardianceEmpagliflozin12$17,999
OzempicSemaglutide15$15,641
EliquisApixaban18$13,602
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$2,076
Rosuvastatin Calcium54$815
Losartan-HydrochlorothiazideLosartan/Hydrochlorothiazide37$662
Sucralfate11$596
Pantoprazole Sodium67$545
Levothyroxine Sodium66$490
Glimepiride18$476
Atorvastatin Calcium89$451
Metoprolol Succinate48$443
Losartan Potassium47$373
Chlorthalidone15$331

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$101$24,29820 claims
Novo NordiskOzempic$236$15,64115 claims
PfizerEliquis$96$13,60218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,505 nurse practitioner providers in Alabama.

Other nurse practitioner in Dothan

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →